When was Infinome Biosciences founded?

Infinome Biosciences was founded in 2020.

Where is Infinome Biosciences located?

Infinome Biosciences is headquartered in St. Louis, United States.

How many employees does Infinome Biosciences have?

As of Dec 31, 2021, Infinome Biosciences has 176 employees, reflecting a 39% year-over-year growth in headcount.

Where does Infinome Biosciences rank among its competitors?

Infinome Biosciences ranks 30th amongst 69 active competitors, of which 20 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was WhiteLab Genomics, which secured $26M in Oct, 2026.

Who are the top competitors of Infinome Biosciences?

Infinome Biosciences' top competitors include Senti Bio, ADARx Pharmaceuticals and CRISPR Therapeutics. Among them, WhiteLab Genomics secured the most recent funding round in October, 2026.

Infinome Biosciences - 2026 Company Profile, Team & Competitors

Infinome Biosciences is an acqui-hired company based in St. Louis (United States), founded in 2020 by Dan Held and Andrew Garst. It operates as a Provider of bioengineering technology to unlock the potential of the genome. The company has 69 active competitors, including 20 funded and 14 that have exited. Its top competitors include companies like Senti Bio, ADARx Pharmaceuticals and CRISPR Therapeutics.

Company Details

Provider of bioengineering technology to unlock the potential of the genome. The company has the GenoScaler platform which uses CRISPR editing, high-throughput smart automation & analytics, predictive fermentation, machine learning, software & informatics to enable rapid engineering of genomes.

Key Metrics

Founded Year

2020

Location

St. Louis, United States

Stage

Acqui-Hired

Ranked

30^th among 69 active competitors

Employee Count

176 as on Dec 31, 2021

Similar Companies

Senti Bio & 84 more

View Infinome Biosciences' full profile

Infinome Biosciences has not raised any funding rounds yet.

The founders of Infinome Biosciences are Dan Held and Andrew Garst.

Here are the details of Infinome Biosciences' key team members:

Dan Held: Co-Founder of Infinome Biosciences.
Contact Info: 1 email address
Andrew Garst: Co-Founder of Infinome Biosciences.

View details of Infinome Biosciences's Founder profiles and Board Members

Infinome Biosciences' employee count trend

Infinome Biosciences has 176 employees as of Dec 21. The total employee count is 39.0% more than what it was in Dec 20. Here is Infinome Biosciences's employee count trend over the years:

Employee count trend for Infinome Biosciences

Uncover Infinome Biosciences' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Infinome Biosciences include Senti Bio, ADARx Pharmaceuticals and CRISPR Therapeutics. Here is the list of Top 10 competitors of Infinome Biosciences, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	68/100
2nd	ADARx Pharmaceuticals 2019, San Diego (United States), Public	Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts	$353M	Bain Capital Life Sciences, T. Rowe Price ... & 17 others	63/100
3rd	CRISPR Therapeutics 2013, Basel (Switzerland), Public	Developer of solutions for treating human genetic diseases by using genome editing technology	$127M	Celgene, New Leaf Venture Partners & 10 others	63/100
4th	Geninus 2018, Seoul (South Korea), Public	Developer of genomic-based disease prevention platform	$13.3M	IMM Investment, Korea Investment Partners ... & 5 others	61/100
5th	Genprex 2009, Austin (United States), Public	Developer of therapeutics to treat cancer at molecular level	$3.11M	Inception Capital Management, TiE ScaleUp ... & 1 others	56/100
6th	WhiteLab Genomics 2019, Paris (France), Series B	Provider of drug discovery and development platform	$36.6M	AVP, Y Combinator & 5 others	55/100
7th	Bota 2019, Lafayette (United States), Series B	Developer of AI-based platform for enzyme and strain engineering	$100M	Sequoia Capital China, BASF & 9 others	55/100
8th	Modular Genetics 2000, Woburn (United States), Series B	Developer of a proprietary, automated system for gene engineering and molecular biology	$8.9M	MassVentures, America’s Seed Fund & 2 others	52/100
9th	Avectas 2011, Dublin (Ireland), Series C	Provider of non-viral cell engineering technology platform for drug discovery	$33.5M	EIC Fund, Europa & 1 others	50/100
10th	GeneScience Pharmaceuticals 1996, Changchun (China), Series B	Provides genetically engineered pharmaceuticals products	-	Haitong Bank, China Huarong Asset Management ... & 3 others	50/100
30th	Infinome Biosciences 2020, St. Louis (United States), Acqui-Hired	Provider of bioengineering technology to unlock the potential of the genome	-	-	33/100